SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
PRANA BIOTECHNOLOGY LIMITED
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Geoffrey Kempler
|
|
|
|
Geoffrey Kempler,
|
|
|
Executive Chairman
|
May 13, 2014
World leader in movement disorders Professor
Ira Shoulson
joins Prana Board
MELBOURNE, AUSTRALIA, MAY 13, 2014:
Prana Biotechnology (ASX:PBT, NASDAQ: PRAN) is pleased to announce Professor Ira Shoulson will join the Company’s Board
of Directors as a Non-Executive Director.
Professor Shoulson is one of the world’s
foremost experts in neurodegenerative diseases and movement disorders, and the founder of international academic consortia the
Huntington Study Group and Parkinson Study Group, which have been instrumental in the development of innovative drugs to treat
these disabling neurological conditions. This is his first company Board position.
Professor Shoulson is Professor of Neurology,
Pharmacology and Human Science at Georgetown University, Washington, DC, USA, and Director of the University’s Program for
Regulatory Science and Medicine (PRSM). He is also principal investigator of the Georgetown University Center of Excellence in
Regulatory Science and Innovation (CERSI), one of four research and education centers currently funded by the Food and Drug Administration
(FDA).
Professor Shoulson has served as a consultant
to, and member of, several FDA advisory committees over the past three decades, and has been involved in eight successful new drug
applications to the FDA, notably long-acting methylphenidate (Concerta©) for attention deficit disorder, rasagiline (Azilect©)
for Parkinson disease, and tetrabenazine (Xenazine©),
the
first drug approved by the FDA for the treatment of chorea in Huntington disease (HD).
Prana Biotechnology CEO and Executive Chairman
Geoffrey Kempler said: “Professor Shoulson’s clinical and regulatory experience will be pivotal as Prana prepares to
meet with regulators later this year to chart the next steps in PBT2’s development as a treatment for Huntington disease.”
Professor Shoulson said joining the Prana
board was an exceptional opportunity to help develop the next generation of treatments for neurodegenerative disorders.
“I have spent my entire professional
life developing treatments aimed at making a difference for patients with Huntington disease, Parkinson disease and similar neurodegenerative
disorders,” he said.
“Based on the Reach2HD study and
ongoing discovery and translational research, I believe PBT2 is among the most promising of experimental treatments intended to
ameliorate the disabling cognitive impairment of HD, which is a major source of disability for our patients.”
“Besides PBT2, Prana has an expanding
library of compounds that are applicable not just to neurological disorders but other disorders including cancer.”
Professor Shoulson’s position as
a non-Executive Director of Prana Biotechnology is effective immediately. Prior to taking up his position with Prana, Professor
Shoulson concluded his elected term as Chair and President of the Huntington Study Group.
- ENDS-
Contacts:
Investor Relations
|
Media Relations
|
Rebecca Wilson
|
Ben Oliver
|
T: +61 3 8866 1216
|
T: +61 3 8866 1233
|
E:
rwilson@buchanwe.com.au
|
E:
boliver@buchanwe.com.au
|
About Prana Biotechnology Limited
Prana Biotechnology was established to
commercialise research into Alzheimer's disease, Huntington disease and other neurodegenerative and movement disorders. The Company
was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers
at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne)
and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s
technology.
Forward Looking Statements
This press
release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section
21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words
as "expects," "intends," "hopes," "anticipates," "believes," "could,"
"may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive
means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's
drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's
drug development program, including, but not limited to, PBT2, and any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or
delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components,
including, but not limited to, PBT2, the ability of the Company to procure additional future sources of financing, unexpected
adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT2,
that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property
or trade secrets, including, but not limited to, the intellectual property relating to PBT2, and other risks detailed from time
to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and
its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially
due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you
should not rely on those forward-looking statements as a prediction of actual future results.